Phase 1 solid tumor biotechnology company Aktis Oncology (AKTS.US) applies for US stock IPO, plans to raise $100 million.

According to the Securities and Exchange Commission (SEC) filing last Friday, Aktis Oncology (AKTS.US), a clinical phase I biotechnology company dedicated to the development of targeted radiopharmaceuticals for solid tumors, is planning to raise up to $100 million through an initial public offering (IPO).